{"entity":{"id":"emactuzumab","kind":"drug","name":"Emactuzumab","aka":[],"tldr":"Emactuzumab is an experimental monoclonal antibody from SynOx Therapeutics in phase 3 trials for tenosynovial giant cell tumour, aimed at CSF1R.","summary":"Emactuzumab is a monoclonal antibody developed by SynOx Therapeutics and Hoffmann-La Roche. Its target is CSF1R (the sponsor names CSF-1R). The sponsor states: Emactuzumab is given as five intravenous infusions once every two weeks; a trial exclusion criterion (prior therapy targeting CSF-1 or CSF-1R) indicates it is a CSF-1R-directed antibody used to treat tenosynovial giant cell tumour by disrupting CSF-1/CSF-1R signalling. ClinicalTrials.gov describes the intervention as: Emactuzumab administered once every 2 weeks (q2w). It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05417789 (Study of Emactuzumab for Tenosynovial Giant Cell Tumour (TGCT)) and NCT03768063 (A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study), in tenosynovial giant cell tumour. The largest, NCT03768063, plans to enrol 1000 participants with primary completion expected 2028-07-05. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Emactuzumab","url":"https://clinicaltrials.gov/search?intr=Emactuzumab"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tenosynovial-giant-cell-tumour"],"sections":[],"technologies":[],"targets":["csf1r"],"drugs":[],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05417789","nct03768063"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"Emactuzumab is given as five intravenous infusions once every two weeks; a trial exclusion criterion (prior therapy targeting CSF-1 or CSF-1R) indicates it is a CSF-1R-directed antibody used to treat tenosynovial giant cell tumour by disrupting CSF-1/CSF-1R signalling.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/emactuzumab/","neighbours":{"cancer":[{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/"}],"target":[{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"trial":[{"id":"nct03768063","kind":"trial","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","route":"/trials/nct03768063/"},{"id":"nct05417789","kind":"trial","name":"Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)","route":"/trials/nct05417789/"}]}}